MedPath

Heart Biomarker Evaluation in Apnea Treatment

Phase 2
Completed
Conditions
Cardiovascular Disease
Obstructive Sleep Apnea
Coronary Artery Disease
Interventions
Other: Healthy Lifestyles and Sleep Education plus PAP
Other: Healthy Lifestyles and Sleep Education plus Supplemental Oxygen
Other: Healthy Lifestyles and Sleep Education
Registration Number
NCT01086800
Lead Sponsor
Brigham and Women's Hospital
Brief Summary

This study examines the role of sleep apnea treatment in improving cardiovascular biomarkers.

Detailed Description

This is a Phase II randomized controlled trial that will evaluate the effects of supplemental nocturnal oxygen or Positive Airway Pressure (PAP) therapy, compared to optimal medical preventive therapy for Cardiovascular Disease (CVD) risk, on biomarkers of CVD risk in Obstructive Sleep Apnea (OSA) patients at high risk for CVD events. The study will focus on patients with moderate to severe OSA but only mild OSA symptoms.

Eligible participants have a history or symptoms of heart disease AND have symptoms of sleep apnea or snoring. Participants will be contributing to medical knowledge about different options that can be used to improve heart disease in people with sleep apnea.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
318
Inclusion Criteria
  • established Coronary Artery Disease or established cardiovascular disease risk factors
  • home sleep test that showed moderately severe sleep apnea
Exclusion Criteria
  • poorly controlled health
  • currently using supplemental oxygen or PAP for OSA

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HLSE plus PAPHealthy Lifestyles and Sleep Education plus PAP-
HLSE plus OxygenHealthy Lifestyles and Sleep Education plus Supplemental Oxygen-
Healthy Lifestyles and Sleep EducationHealthy Lifestyles and Sleep Education-
Primary Outcome Measures
NameTimeMethod
To compare the effects of nocturnal supplemental oxygen and PAP versus optimized medical management on biomarkers of cardiovascular risk, including:3 months

* 24 hour blood pressure (BP) profile

* Markers of systemic inflammation

* Markers of oxidative stress

* Prothrombotic markers

* Sympathetic nervous system activity

* Cardiac rhythm, impulse generation and ischemia

* Dyslipidemia

* Glucose regulation

* Myocardial stress

Secondary Outcome Measures
NameTimeMethod
Compare the effects of nocturnal supplemental oxygen and PAP versus standard care on patient-reported outcomes, including:3 months

* vitality

* self reported sleepiness

Compare nocturnal supplemental oxygen and PAP on measures of:3 months

* efficacy (AHI, hypoxemia)

* adherence

* side effects

Trial Locations

Locations (4)

Case Western Reserve University

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland, Ohio, United States

Johns Hopkins University

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

Partners HealthCare

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

VA Boston Healthcare System

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath